Akari Therapeutics | 8-K: Akari Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights
Akari Therapeutics | 8-K: Current report
Akari Therapeutics | 8-K: Current report
Akari Therapeutics | 8-K: Current report
Akari Therapeutics | 8-K: Current report
Akari Therapeutics | 8-K: Current report
Akari Therapeutics | 8-K: Current report
Akari Therapeutics | 8-K: Current report
Akari Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Akari Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Akari Therapeutics | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing
Akari Therapeutics | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing
Akari Therapeutics | F-3: Registration statement for specified transactions by certain foreign private issuers
Akari Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Akari Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Akari Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Akari Therapeutics | F-6 POS: Post-effective amendment to a F-6EF registration
Akari Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Akari Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Akari Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
No Data